Lecanemab
BAN2401-G000-301
Phase 3 small_molecule active
Quick answer
Lecanemab for Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia. is a Phase 3 program (small_molecule) at Eisai GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eisai GmbH
- Indication
- Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active